Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/APP_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/APP_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/APP_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/APP_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/APP_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/APP_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/APP_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/APP_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/APP_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/APP_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/APP_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00217822 | Skin | AK | glial cell development | 24/1910 | 116/18723 | 5.74e-04 | 5.11e-03 | 24 |
GO:00508031 | Skin | AK | regulation of synapse structure or activity | 38/1910 | 218/18723 | 7.06e-04 | 6.01e-03 | 38 |
GO:00716748 | Skin | AK | mononuclear cell migration | 35/1910 | 196/18723 | 7.20e-04 | 6.10e-03 | 35 |
GO:20004044 | Skin | AK | regulation of T cell migration | 12/1910 | 42/18723 | 7.34e-04 | 6.20e-03 | 12 |
GO:00508073 | Skin | AK | regulation of synapse organization | 37/1910 | 211/18723 | 7.35e-04 | 6.20e-03 | 37 |
GO:000975517 | Skin | AK | hormone-mediated signaling pathway | 34/1910 | 190/18723 | 8.18e-04 | 6.80e-03 | 34 |
GO:000717910 | Skin | AK | transforming growth factor beta receptor signaling pathway | 35/1910 | 198/18723 | 8.69e-04 | 7.17e-03 | 35 |
GO:00510909 | Skin | AK | regulation of DNA-binding transcription factor activity | 66/1910 | 440/18723 | 8.99e-04 | 7.40e-03 | 66 |
GO:000918525 | Skin | AK | ribonucleoside diphosphate metabolic process | 22/1910 | 106/18723 | 9.13e-04 | 7.49e-03 | 22 |
GO:001407419 | Skin | AK | response to purine-containing compound | 28/1910 | 148/18723 | 9.46e-04 | 7.63e-03 | 28 |
GO:20004014 | Skin | AK | regulation of lymphocyte migration | 15/1910 | 61/18723 | 9.64e-04 | 7.68e-03 | 15 |
GO:00487084 | Skin | AK | astrocyte differentiation | 18/1910 | 81/18723 | 1.14e-03 | 8.81e-03 | 18 |
GO:000808816 | Skin | AK | axo-dendritic transport | 17/1910 | 75/18723 | 1.22e-03 | 9.32e-03 | 17 |
GO:001003828 | Skin | AK | response to metal ion | 57/1910 | 373/18723 | 1.26e-03 | 9.52e-03 | 57 |
GO:00000865 | Skin | AK | G2/M transition of mitotic cell cycle | 26/1910 | 137/18723 | 1.35e-03 | 1.00e-02 | 26 |
GO:000828610 | Skin | AK | insulin receptor signaling pathway | 23/1910 | 116/18723 | 1.36e-03 | 1.01e-02 | 23 |
GO:003286819 | Skin | AK | response to insulin | 43/1910 | 264/18723 | 1.37e-03 | 1.02e-02 | 43 |
GO:003010019 | Skin | AK | regulation of endocytosis | 36/1910 | 211/18723 | 1.42e-03 | 1.05e-02 | 36 |
GO:004819319 | Skin | AK | Golgi vesicle transport | 47/1910 | 296/18723 | 1.46e-03 | 1.06e-02 | 47 |
GO:000913525 | Skin | AK | purine nucleoside diphosphate metabolic process | 21/1910 | 103/18723 | 1.50e-03 | 1.08e-02 | 21 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0501023 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501033 | Breast | IDC | Alzheimer disease | 107/867 | 384/8465 | 1.70e-23 | 7.88e-22 | 5.90e-22 | 107 |
hsa0502233 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0501044 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa0501054 | Cervix | N_HPV | Alzheimer disease | 41/349 | 384/8465 | 1.50e-08 | 3.13e-07 | 2.45e-07 | 41 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa050101 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa050221 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa050102 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
hsa050222 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
hsa050103 | Colorectum | SER | Alzheimer disease | 146/1580 | 384/8465 | 6.52e-20 | 2.40e-18 | 1.75e-18 | 146 |
hsa050223 | Colorectum | SER | Pathways of neurodegeneration - multiple diseases | 168/1580 | 476/8465 | 6.23e-19 | 2.07e-17 | 1.50e-17 | 168 |
hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
APP | SNV | Missense_Mutation | novel | c.1701G>C | p.Gln567His | p.Q567H | P05067 | protein_coding | tolerated(0.1) | possibly_damaging(0.906) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
APP | SNV | Missense_Mutation | rs201093867 | c.710N>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
APP | SNV | Missense_Mutation | | c.533A>G | p.Lys178Arg | p.K178R | P05067 | protein_coding | tolerated(1) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | | c.853G>C | p.Glu285Gln | p.E285Q | P05067 | protein_coding | tolerated(0.17) | benign(0.403) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
APP | SNV | Missense_Mutation | rs199549173 | c.1406N>A | p.Arg469His | p.R469H | P05067 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs760615902 | c.1666N>A | p.Glu556Lys | p.E556K | P05067 | protein_coding | deleterious(0.01) | benign(0.132) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs200521782 | c.1690G>C | p.Glu564Gln | p.E564Q | P05067 | protein_coding | deleterious(0.01) | possibly_damaging(0.757) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
APP | SNV | Missense_Mutation | rs201093867 | c.710T>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | | c.124N>C | p.Asn42His | p.N42H | P05067 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
APP | SNV | Missense_Mutation | rs201093867 | c.710T>G | p.Val237Gly | p.V237G | P05067 | protein_coding | tolerated(0.37) | benign(0.018) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | GENTIAN VIOLET | GENTIAN VIOLET | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | ALZ-801 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Affitope AD-01 | | 22506132 |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | AAB-003/PF-05236812 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | CHEMBL2109300 | GSK933776 | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | MABT5102A | CRENEZUMAB | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | MER-5101 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | AAB-002 | | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Gantenerumab | GANTENERUMAB | |
351 | APP | DRUGGABLE GENOME, PROTEASE INHIBITOR, CELL SURFACE | | Systebryl | | |